Proof-point cadence: the last promised marker just landed, and the next one is already on the clock
The model's full reasoning — Q1 2017 call → NOWe need answer YES/NO. Need analyze transcript for live checkable sequence of proof points with both just delivered marker and next marker named near. Need management's own words coherent posture. Let's parse transcript. Management discusses many things. Need find specific operational step just completed and next step on same path with timing. Examples: Cepheid received FDA clearance for Xpert Xpress flu/RSV in March. That's a product launch/approval just delivered. Next marker? They mention omni platform launch expected early next year (first part next year, maybe Q1). Is that same path? Cepheid product pipeline? The FDA clearance is a specific product launch. The omni platform is a next platform launch with timing. But is it "same forward path"? Both are Cepheid product launches/expansions. Management says "we're looking at probably the first, early part of next year, maybe even as early as first quarter next year for that launch" in response to analyst question. That is management adopting? Yes, Tom Joyce says. But is the FDA clearance a "marker just delivered" that management presents as checkpoint passed on path? They mention "Cepheid also received FDA clearance for its Xpert Xpress flu and RSV respiratory virus test in March. Both of these tests deliver molecular results in as little as 20 minutes, twice as fast as their predecessors..." That's a product launch/approval. Then later in Q&A, Tom discusses omni platform launch timing. Is that a sequence? Maybe. Another example: Beckman launched Biomek i-Series automated workstations during quarter. That's a product launch. Next marker? Not necessarily. Another: Pall featured innovations at trade show, not launch. Another: Acquisition AVT announced, expected close Q2. That's a next step? They announced acquisition, subject to closing, expected Q2. That's a near-term next step but not a "just delivered" marker? They announced it, not closed. Not a sequence. Another: Two acquisitions announced for nearly $100M expected close Q2. That's next step but no just delivered marker on same path. Another: Hach CM130 coring monitoring system cleared by FDA, developed with dialysis provider. That's a product clearance just delivered. Next marker? Not named. Another: Cepheid omni platform launch early next year.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CMPS | COMPASS Pathways plc | Q3 2023 | 2023-11-04 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| HIW | Highwoods Properties, Inc. | Q4 2022 | 2023-02-08 | B |
| TCBI | Texas Capital Bancshares, Inc. | Q2 2021 | 2021-07-21 | F |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| CLMT | Calumet Specialty Products Partners, L.P | Q1 2018 | 2018-05-16 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| SCVL | Shoe Carnival, Inc. | Q4 2017 | 2018-03-27 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| INSM | Insmed Incorporated | Q4 2017 | 2018-02-23 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
XOM · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES Management presents a live, checkable sequence of proof points. In Neil Chapman's remarks, he explicitly notes that the Coral Floating LNG project is "progressing on schedule" and that "fabrication of the hull is expected to start in the third quarter of this year" — a concrete, near-term operational checkpoint 3–4 months away. Immediately prior, he states that "earlier this month, we announced that the development plan for the first phase has been submitted," treating that submission as the just-completed marker on the same path. He anchors the next step as "targeting final investment decision in 2019" with 2024 first LNG, presented as scheduled and already in motion rather than aspirational. This forms one coherent posture: the company is executing a verifiable execution sequence on the Mozambique LNG opportunity, with the development-plan submission just cleared and FID locked for 2019. Other examples (Baytown ethane cracker operations begun yesterday; 50 new Permian wells brought to sales in the quarter) exist, but the Mozambique LNG thread satisfies both required elements on a single forward path. No other elements (financial beats, routine maintenance, or analyst questions) are used to construct the sequence.
MKC · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing the Frank's and French's integration as a completed checkpoint ("With the acquisition and integration complete"), then immediately naming and anchoring the next concrete steps on the same path — such as launching the first dedicated mustard campaign in the U.S. (kicked off this week during the call) and 2018 U.S. national TV advertising for Frank's in the second half — as scheduled, in-motion activities that will drive further growth. This is presented as one coherent execution sequence rather than isolated results. Other elements like distribution gains and summer grilling promotions are tied directly to this progression. No routine or vague items qualify; 2018 advertising and marketing acceleration are explicitly tied to the post-integration trajectory.
CMPS · Q3 2023 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing progress as a live execution sequence: the open-label PTSD Phase II study has just reached full recruitment (a concrete checkpoint passed), and they explicitly name the next marker — top-line readout this year — as the immediate follow-on step already in motion and scheduled within the coming months. This is presented as part of the same forward trajectory they are tracking, alongside the TRD Phase III where site initiations (3/4 of COMP005) are described as continuing to advance toward the summer 2024 readout.